Celator Pharma Reports New Data for VYXEOS in FLT3-ITD Mutated AML Cells Derived from Patients with Newly Diagnosed AML to be Presented in AACR Annual Meeting

Celator Pharmaceuticals, Inc.

today announced that data for VYXEOS™ (cytarabine:daunorubicin) Liposome for Injection (also known as CPX-351), its lead product candidate, will be presented at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, LA, April 16-20, 2016. The research was conducted in the laboratory of Dr. Jeffrey Tyner at Oregon Health & Science University. The objective of the research was to examine the ex vivo sensitivity of acute myeloid leukemia (AML) cells derived from newly diagnosed patients to VYXEOS. This work supports the observed clinical benefit of VYXEOS in high-risk AML patients and may provide a means of identifying patient genotypes/phenotypes most sensitive to VYXEOS. "We continue to learn more about the unique activity of VYXEOS in AML and enhance our ability to match this performance with specific patient characteristics that could be predictive of improved outcomes," said Lawrence Mayer, Ph.D., President and Chief Scientific Officer at Celator. "The research being undertaken by Dr. Tyner reflects Celator's goal to elucidate the clinical benefits of VYXEOS by expanding our scientific understanding of its mechanism of action, particularly in AML cells with important molecular phenotypes." Details on the AACR poster presentation: Presentation Title: CPX-351 cytotoxicity against fresh AML blasts is increased for FLT3-ITD+ cells and correlates with drug uptake and clinical outcomes Date/Time: Sunday, April 17, 2016 – 1:00pm-5:00pm Session Category: Poster Presentation Session Title: ET01-03, Combination Chemotherapy Location: New Orleans Convention Center, Halls G-J Poster Section 15 Abstract Number: 287 The poster will be available on Celator's website (www.celatorpharma.com) at the conclusion of the AACR meeting.